| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real life efficacy and safety of direct-acting antiviral therapy for treatment of hepatitis C-infected patients with genotypes 1, 2 and 3 in northwest China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ying Yang, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Ya-Ping Li, Xin Zhang and Shuang-Suo Dang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shuang-Suo Dang, MD, PhD, Academic Fellow, Academic Research, Doctor, Doctor, Professor, Infectious Disease, the Second Affiliated hospital of Xi'An Jiaotong University, Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'An, Shannxi Province, China. dang212@126.com, Xi'An 710004, Shaanxi Province, China. dang212@126.com |
| Key Words |
Hepatitis C; Direct-acting antiviral agents; Efficacy; Safety; Drug-drug interactions; Real-life experience |
| Core Tip |
Direct-acting antiviral agents (DAAs) based regimens are currently the preferred treatment for hepatitis C. However, there is not enough data reporting the results of real-world research, especially in countries such as China where DAAs have only been approved for using in recent years. We found that there was no significant difference in sustained virological responses (SVR) between patients with different genotypes and liver statuses. Patients with lower alanine aminotransferase levels at baseline who achieved end of treatment response were more likely to achieve SVR at post-treatment week 12. Also, we found two cases of special adverse events. One case involved facial and bilateral lower extremity edemas, which was due to drug-drug interactions and the other case showed an interesting change in lipid levels while the patient was on medication. |
| Publish Date |
2019-11-28 10:38 |
| Citation |
Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of hepatitis C-infected patients with genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i44.6551 |
